Trusted Resources: Education
Scientific literature and patient education texts
Mucopolysaccharidosis Type 1 (MPS 1)
source: The Children’s Hospital of Philadelphia
year: N/A
summary/abstract:What is Mucopolysaccharidosis Type 1?
Mucopolysaccharidosis type 1 (MPS 1) is a rare lysosomal storage disorder characterized by an abnormal build-up of various toxic materials, called glycosaminoglycans (GAGs) in the body’s cells. MPS 1 is a spectrum of disease ranging from a mild (attenuated) form, called Scheie, to severe disease, called Hurler syndrome. Hematopoietic stem cell transplantation and/or enzyme replacement therapy is the mainstay of treatment for individuals with severe MPS 1.
Causes of Mucopolysaccharidosis Type 1
MPS 1 is a genetic condition caused by disease-causing (pathogenic) changes in the IDUA gene. The IDUA gene provides the body with the instructions it needs to produce the alpha-L-iduronidase enzyme. The role of this enzyme is to break down the GAGs in the body. If the body does not produce enough of this enzyme, GAGs build up in various parts of the body and cause symptoms of disease.
MPS 1 is inherited in an autosomal recessive manner. This means that in order to have the condition, an individual needs to have two disease-causing changes in the DNA. One change must be present in the copy of the IDUA gene that the individual inherits from their mother, and another change must be present in the copy of the IDUA gene the individual inherits from their father. In individuals with MPS 1, neither copy of the IDUA gene is able to provide the proper instructions to produce the enzyme.
read more
Related Content
-
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market Research Report – Global Clinical Trials Review, H2, ...The "Mucopolysaccharidosis I (MPS I) (Hu...
-
Mucopolysaccharidoses Type I Gene TherapyMucopolysaccharidoses type I (MPS I) is ...
-
Steve HollandSteve Holland, CPA is the proud father o...
-
Mount Sinai – Lysosomal Storage Disease ProgramThe Mount Sinai Hospital’s Lysosomal S...
-
UCSF – Lysosomal Storage Disease CenterThe UCSF Lysosomal Storage Disease Cente...
-
Inhibition of Iduronic Acid Biosynthesis by Ebselen Reduces Glycosaminoglycan Accumulation in Mucopolysaccharidosis ...Mucopolysaccharidosis type I (MPS-I) is ...
-
Mucopolysaccharidoses Diagnosis in the Era of Enzyme Replacement Therapy in EgyptUndegraded glycosaminoglycans (GAGs) ind...